The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
Abstract
BACKGROUND & AIMS: Inflammatory bowel disease (IBD) is characterised by chronic intestinal inflammation, resulting from dysregulation of the mucosal immune system and compromised intestinal epithelial barrier function. The bile salt, nuclear farnesoid X receptor (FXR), was recently implicated in intestinal antibacterial defence and barrier function. The aim of this study was to investigate the therapeutic potential of FXR agonists in the treatment of intestinal inflammation in complementary in vivo and in vitro models. METHODS: Colitis was induced in wild-type (WT) and Fxr-null mice using dextran sodium sulfate, and in WT mice using trinitrobenzenesulfonic acid. Mice were treated with vehicle or the FXR agonist INT-747, and colitis symptoms were assessed daily. Epithelial permeability assays and cytokine expression analysis were conducted in mouse colon and enterocyte-like cells (Caco-2/HT29) treated with medium or INT-747. Inflammatory cytokine secretion was determined by ELISA in various human immune cell types. RESULTS: INT-747-treated WT mice are protected from DSS- and TNBS-induced colitis, as shown by significant reduction of body weight loss, epithelial permeability, rectal bleeding, colonic shortening, ulceration, inflammatory cell infiltration and goblet cell loss. Furthermore, Fxr activation in intestines of WT mice and differentiated enterocyte-like cells downregulates expression of key proinflammatory cytokines and preserves epithelial barrier function. INT-747 significantly decreases tumour necrosis factor α secretion in activated human peripheral blood mononuclear cells, purified CD14 monocytes and dendritic cells, as well as in lamina propria mononuclear cells from patients with IBD. CONCLUSIONS: FXR activation prevents chemically induced intestinal inflammation, with improvement of colitis symptoms, inhibition of epithelial permeability, and reduced goblet cell loss. Furthermore, FXR activation inhibits proinflammatory cytokine production in vivo in the mouse colonic mucosa, and ex vivo in different immune cell populations. The findings provide a rationale to explore FXR agonists as a novel therapeutic strategy for IBD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FXR agonists are known to alleviate endoplasmic reticulum stress and suppress oxidative damage by upregulating antioxidant and anti-apoptotic pathways [42, 43].”
From High-throughput human microfluidic organoid-on-a-chip platform for modeling liver diseases and screening nanotherapeutics. (2026) · cites this paper as [42]
In the citing paper
“Multiple reports regarding TGR5 function (Gadaleta et al., 2011;Hartmann et al., 2018;Inagaki et al., 2006;Vavassori et al., 2009) have indicated that a very fine balance between host-and microbiota-produced bile acids is required to support epithelial barrier function and control the inflammatory response in the intestine.”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Gadaleta et al., 2011
In the citing paper
“Activation of FXR inhibits intestinal inflammation and protects the intestinal barrier in IBD (Gadaleta et al., 2011).”
From Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway (2023) · cites this paper as Gadaleta et al., 2011
In the citing paper
“Accordingly, FXR activation by agonists GW4064 or obeticholic acid (OCA) attenuates mucosal injury, ileal barrier permeability, bacterial overgrowth and bacterial translocation in mice and rats 20,21,141,142.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [21]
In the citing paper
“treatment with a synthetic agonist of BAR has protective effects in mouse models of colitis, whereas BAR-deficient (Nr1h4−/−) mice exhibit exacerbated pathology (Gadaleta et al., 2011; Vavassori et al., 2009).”
From Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System (2017) · cites this paper as Gadaleta et al., 2011
In the citing paper
“In the small intestine, they are also very important for the maintenance of epithelial barrier function (Gadaleta et al., 2011; Inagaki et al., 2006).”
From Microbiota-related Changes in Bile Acid & Tryptophan Metabolism are Associated with Gastrointestinal Dysfunction in a Mouse Model of Autism (2017) · cites this paper as Gadaleta et al., 2011
Citations
Cites
Podolsky, D. K. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020831 · Cited by 3,183
Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989) · Gastroenterology · doi:10.1016/s0016-5085(89)80072-1 · Cited by 2,396
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis
Sartor, R. B. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0528 · Cited by 1,806
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422 · cited 1×
“Currently, phase 1 and 2 studies with INT-747 are being performed in patients with metabolic and chronic liver diseases, indicating the safe applicability of this class of compounds for the treatment of human disease.(42) Figure 8 INT-747 inhibits IFNg, IL-17 and TNFa production by lymphocyte-enriched LPMCs from IBD p…”
BackgroundPenna, G., & Adorini, L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2405 · Cited by 1,257
Self-citationRegulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
Inagaki, T., Moschetta, A., Lee, Y.-K., Peng, L., Zhao, G., Downes, M., Yu, R. T., Shelton, J. M., Richardson, J. A., Repa, J. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509592103 · Cited by 1,164 · cited 2×
“Fxr-null mice exhibited compromised intestinal integrity at baseline, with further deterioration after bile duct ligation, which was not prevented by FXR agonist treatment.(15) Recently, FXR activation was also shown to protect against hepatic inflammation presumably by repression of NF-kB signalling in mice.”
BackgroundSelf-citationAngiogenins: a new class of microbicidal proteins involved in innate immunity
Hooper, L. V., Stappenbeck, T. S., Hong, C. V., & Gordon, J. I. (2003) · Nature Immunology · doi:10.1038/ni888 · Cited by 947
Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D. J., & Suchy, F. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011610200 · Cited by 804
Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function
Cario, E., Gerken, G., & Podolsky, D. K. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.056 · Cited by 697
Cited by
Sorted by citations
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,820
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
Jia, W., Xie, G., & Jia, W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.119 · Cited by 1,924
Gut microbiota-derived metabolites as key actors in inflammatory bowel disease
Lavelle, A., & Sokol, H. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0258-z · Cited by 2,015
Gut microbiota and IBD: causation or correlation?
Ni, J., Wu, G. D., Albenberg, L., & Tomov, V. T. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.88 · Cited by 1,778
Bile Acid Metabolism and Signaling
Chiang, J. Y. L. (2013) · Comprehensive physiology · doi:10.1002/cphy.c120023 · Cited by 1,662
“OCA antagonizes NF-κB-stimulated inflammation in liver (203), modulates innate immunity in animal models of colitis (197), inhibits and preserves the intestinal barrier in inflammatory bowel disease (69), and inhibits vascular smooth muscle cell inflammation and migration (119).”
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
“Treatment of isolated human mononuclear cells with the FXR agonist obeticholic acid (INT- 747) decreased TNFa secretion and prevented differentiation of CD14? monocytes into dendritic cells (Gadaleta et al. 2011).”
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“These downstream elements then regulate the expression levels of pro-fibrotic target genes such as type I collagen (COL1A1), metalloproteinase inhibitors (TIMPs), and MMPs but also the apoptosis regulator Bcl 2, resulting in cell proliferation and survival [17].”
BackgroundBile acids and the gut microbiota: metabolic interactions and impacts on disease
Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D., & Patterson, A. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00805-x · Cited by 1,214
Wang, K., Liao, M., Zhou, N., Bao, L., Ma, K., Zheng, Z., Wang, Y., Liu, C., Wang, W., Wang, J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.028 · Cited by 1,174
The intestinal microbiota fuelling metabolic inflammation
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0198-4 · Cited by 1,089
Commensal bacteria at the interface of host metabolism and the immune system
Brestoff, J. R., & Artis, D. (2013) · Nature Immunology · doi:10.1038/ni.2640 · Cited by 945
Chávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.055 · Cited by 970
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931
“Interestingly, OCA also enhances colonic expression of cathelicidin, a natural antibiotic with microbicidal properties, suggesting its capacity to modulate the gut microbiota.(48) The gut microbiota has recently been shown to influence the size and composition of the bile acid pool throughout the enterohepatic system…”
BackgroundSelf-citationBile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
Postler, T. S., & Ghosh, S. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.05.008 · Cited by 876
“Correspondingly, treatment with a synthetic agonist of BAR has protective effects in mouse models of colitis, whereas BAR-deficient (Nr1h4 / ) mice exhibit exacerbated pathology (Gadaleta et al., 2011; Vavassori et al., 2009).”
BackgroundDysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation
Sinha, S. R., Haileselassie, Y., Nguyen, L. P., Tropini, C., Wang, M., Becker, L. S., Sim, D., Jarr, K. J., Bishop, E. S., Singh, G., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2020.01.021 · Cited by 880
Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis
Cai, J., Sun, L., & Gonzalez, F. J. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.02.004 · Cited by 892
Pathological bacterial translocation in liver cirrhosis
Wiest, R., Lawson, M. A., & Geuking, M. B. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.044 · Cited by 826
“Conjugated bile acids are natural ligands for several nuclear receptors, of which the transcription factor farnesoid X receptor (FxR) has gained much attention [75].”
BackgroundHigh-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review
Malesza, I. J., Malesza, M., Walkowiak, J., Mussin, N. M., Walkowiak, D., Aringazina, R. A., Bartkowiak-Wieczorek, J., & Mądry, E. (2021) · Cells · doi:10.3390/cells10113164 · Cited by 847
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738
Bile acid receptors as targets for drug development
Schaap, F. G., Trauner, M., & Jansen, P. L. M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.151 · Cited by 696
Yang, W., & Cong, Y. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00661-4 · Cited by 715
Mouries, J., Brescia, P., Silvestri, A., Spadoni, I., Sorribas, M., Wiest, R., Mileti, E., Galbiati, M., Invernizzi, P., Adorini, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.005 · Cited by 688
Self-citationInflammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues
Lee, M., & Chang, E. B. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.056 · Cited by 645
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634
Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis
Wang, J., Zhu, N., Su, L., Gao, Y., & Yang, R. (2023) · Cells · doi:10.3390/cells12050793 · Cited by 649
The Gut Microbiota in Inflammatory Bowel Disease
Qiu, P., Ishimoto, T., Fu, L., Zhang, J., Zhang, Z., & Liu, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.733992 · Cited by 654
Gasaly, N., de Vos, P., & Hermoso, M. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658354 · Cited by 611
Interaction of gut microbiota with bile acid metabolism and its influence on disease states
Staley, C. M., Weingarden, A. R., Khoruts, A., & Sadowsky, M. J. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-8006-6 · Cited by 595
“A recent study revealed that treatment with an FXR agonist is protective in mouse models of chemically induced colitis (Gadaleta et al. 2011).”
BackgroundBile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy
Chiang, J. Y. L., & Ferrell, J. M. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00223.2019 · Cited by 580
Bile Acids Activated Receptors Regulate Innate Immunity
Fiorucci, S., Biagioli, M., Zampella, A., & Distrutti, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01853 · Cited by 580
“(32), that have observed a reduced number of activated DCs in the colon of colitic mice administered with INT-747/obeticholic acid (32).”
BackgroundInfluentialFleishman, J. S., & Kumar, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01811-6 · Cited by 615
Bile Acid Metabolism in Liver Pathobiology
Chiang, J. Y. L., & Ferrell, J. M. (2018) · Gene Expression · doi:10.3727/105221618x15156018385515 · Cited by 571
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
Zeng, H., Umar, S., Rust, B., Lazarova, D., & Bordonaro, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051214 · Cited by 480
“As a consequence, the inactivation or mutation of FXR leads to the pro-inflammatory status in the colon [89,90].”
BackgroundBile acid nuclear receptor FXR and digestive system diseases
Ding, L., Yang, L., Wang, Z., & Huang, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.01.004 · Cited by 477
Molecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
Sun, L., Cai, J., & Gonzalez, F. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00404-2 · Cited by 459
Targeting the gut-liver axis in liver disease
Wiest, R., Albillos, A., Trauner, M., Bajaj, J. S., & Jalan, R. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.007 · Cited by 427
Bile acids as modulators of gut microbiota composition and function
Larabi, A. B., Masson, H. L. P., & Bäumler, A. J. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2172671 · Cited by 443
“In chemically induced colitis mouse models, FXRdeficiency worsens, while treatment with the FXR agonist obeticholic acid protects from mucosal inflammation and promotes the expression of antibacterial genes.(73) Obeticholic acid-mediated activation of FXR decreases TNF-α production in several immune cell populations e…”
BackgroundInfluentialBile acid transporters and regulatory nuclear receptors in the liver and beyond
Halilbasic, E., Claudel, T., & Trauner, M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.002 · Cited by 415
“Under normal conditions, BA-activated FXR controls bacterial overgrowth and maintains the epithelial barrier integrity by induction of multiple anti-inflammatory genes [103] and pharmacological activation of FXR has beneficial effects in the mouse model of colitis [104].”
BackgroundFXR signaling in the enterohepatic system
Matsubara, T., Li, F., & Gonzalez, F. J. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.05.004 · Cited by 383
“6-ECDCA, also known as INT-747, is another efficacious FXR agonist under testing for various diseases associated with bile acid dysfunction, such as liver fibrosis (Fiorucci et al., 2004) and inflammatory bowel disease (Gadaleta et al., 2011).”
BackgroundInfluentialDiet in the Pathogenesis and Treatment of Inflammatory Bowel Diseases
Lee, D. Y., Albenberg, L. G., Compher, C. W., Baldassano, R. N., Piccoli, D. A., Lewis, J. D., & Wu, G. D. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.01.007 · Cited by 388
Golubeva, A. V., Joyce, S. A., Moloney, G., Burokas, A., Sherwin, E., Arboleya, S., Flynn, I., Khochanskiy, D., Moya-Pérez, A., Peterson, V., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.09.020 · Cited by 364
“In N U In the small intestine, they are also very important for the maintenance of epithelial barrier function (Gadaleta et al., 2010; Inagaki et al., 2006).”
Hofmann, A. F., & Hagey, L. R. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r049437 · Cited by 365
The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases
Baldelli, V., Scaldaferri, F., Putignani, L., & CHIERICO, F. D. (2021) · Microorganisms · doi:10.3390/microorganisms9040697 · Cited by 389
“, Farnesoid X receptor (FXR)), inferring that the dysbiosis of the gut microbiota’s characteristic of IBDs may alter the capacity for BA modification in this community [103].”
BackgroundThe Function and Role of the Th17/Treg Cell Balance in Inflammatory Bowel Disease
Yan, J., Luo, M., Chen, Z., & He, B. (2020) · Journal of Immunology Research · doi:10.1155/2020/8813558 · Cited by 365
“Clinical observation of using FXR agonist to stimulate IBD patients showed that the secretion of proinflammatory cytokines IL-17, IFN-γ, and TNF in lamina propria mononuclear cells was significantly decreased [65].”
Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer
Li, T., & Apte, U. M. (2015) · Advances in pharmacology · doi:10.1016/bs.apha.2015.04.003 · Cited by 336
“For example, FXR modulates intestine immunity and FXR activation was shown to reduce inflammation in inflammatory bowel disease (Gadaleta et al., 2011; Vavassori,Mencarelli, Renga,Distrutti, & Fiorucci, 2009).”
BackgroundConnecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex
Rizzetto, L., Fava, F., Tuohy, K. M., & Selmi, C. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.05.008 · Cited by 331
Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets
Santana, P. T., Rosas, S. L. B., Ribeiro, B. E., Marinho, Y., & de Souza, H. S. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073464 · Cited by 359
Emerging roles of bile acids in mucosal immunity and inflammation
Chen, M. L., Takeda, K., & Sundrud, M. S. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0162-4 · Cited by 305
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., Wang, L., Griffiths, C., Brown, M. L., Scott, W. E., et al. (2022) · Nature · doi:10.1038/s41586-022-05594-0 · Cited by 299
Discovery of farnesoid X receptor and its role in bile acid metabolism
Chiang, J. Y. L., & Ferrell, J. M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111618 · Cited by 305
van Diepen, J. A., Berbée, J. F. P., Havekes, L. M., & Rensen, P. C. N. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.02.028 · Cited by 297
Liu, X., Zhang, Y., Li, W., Zhang, B., Yin, J., Liuqi, S., Wang, J., Peng, B., & Wang, S. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c06417 · Cited by 289
Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon
Ward, J. B. J., Lajczak, N. K., Kelly, O. B., O’Dwyer, A. M., Giddam, A. K., Ní Gabhann, J., Franco, P., Tambuwala, M. M., Jefferies, C. A., Keely, S., et al. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00256.2016 · Cited by 286
“In this regard, several bile acid receptors are expressed in the colonic epithelium, including TGR5 and the nuclear receptors farnesoid X receptor, pregnane X receptor, and vitamin D receptor, each of which has been shown to protect against colonic inflammation in animal models (12, 29, 35, 40).”
BackgroundBishehsari, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i20.6055 · Cited by 277
Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease
Hegyi, P., Maléth, J., Walters, J. R., Hofmann, A. F., & Keely, S. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00054.2017 · Cited by 269
Verbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., Elst, I. V., Windmolders, P., Vanuytsel, T., Nevens, F., et al. (2014) · Hepatology · doi:10.1002/hep.26939 · Cited by 258
“ily, has been found to be crucial in numerous hepatobiliary(23-25) and gastrointestinal diseases.(26) FXR is highly expressed in the normal liver, kidney, and intestine.”
BackgroundSorribas, M., Jakob, M. O., Yılmaz, B., Li, H., Stutz, D., Noser, Y., Gottardi, A. D., Moghadamrad, S., Hassan, M., Albillos, A., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.017 · Cited by 258
Leaky Gut: Effect of Dietary Fiber and Fats on Microbiome and Intestinal Barrier
Usuda, H., Okamoto, T., & Wada, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147613 · Cited by 277
Microbiota Metabolites in Health and Disease
McCarville, J. L., Chen, G. Y., Cuevas, V. D., Troha, K., & Ayres, J. S. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-071219-125715 · Cited by 255
Joyce, S. A., & Gahan, C. G. M. (2016) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-041715-033159 · Cited by 241
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Adorini, L., Pruzanski, M., & Shapiro, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.012 · Cited by 259
Self-citationVerbeke, L., Mannaerts, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, I., Windmolders, P., Farre, R., Wenes, M., Mazzone, M., et al. (2016) · Scientific Reports · doi:10.1038/srep33453 · Cited by 236
Hu, J., Wang, C., Huang, X., Yi, S., Su, P., Zhang, Y., Yuan, G., Cao, Q., Ye, X., & Li, H. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109726 · Cited by 236
Bile acid metabolism and signalling in liver disease
Fuchs, C. D., Simbrunner, B., Baumgartner, M., Campbell, C., Reiberger, T., & Trauner, M. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.032 · Cited by 265
Diet, genetics, and the gut microbiome drive dynamic changes in plasma metabolites
Fujisaka, S., Avila-Pacheco, J., Soto, M., Kostic, A., Dreyfuss, J. M., Pan, H., Ussar, S., Altindis, E., Li, N., Bry, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.060 · Cited by 231
“For example, primary bile acids are converted to secondary bile acids by gut microbiotas, and these secondary bile acids not only aid in fat absorption, but they also are reabsorbed into the circulation, where they serve as ligands for the bile acid receptors farnesoid X (FXR) and TGR5 on host cells, leading to effect…”
BackgroundGut–liver axis, cirrhosis and portal hypertension: the chicken and the egg
Arab, J. P., Martín‐Mateos, R., & Shah, V. H. (2017) · Hepatology International · doi:10.1007/s12072-017-9798-x · Cited by 233
“On the other hand, it has been described that FXR activation markedly inhibits inflammation and preserves the intestinal barrier function reducing bacterial translocation in inflammatory bowel disease [80] and in a rat model of cholestatic liver injury [81] (Fig.”
Intestinal Bacteria Interplay With Bile and Cholesterol Metabolism: Implications on Host Physiology
Molinero, N., Ruíz, L., Sánchez, B., Margollés, A., & Delgado, S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00185 · Cited by 233
“The gut microbiota-mediated biotransformation of the BA pool regulates BAs signaling by affecting the activation of host BA receptors such as the nuclear receptor farnesoid X receptor (FXR), which governs bile, glucose and lipid metabolism (Gadaleta et al., 2011).”
BackgroundThe changing metabolic landscape of bile acids – keys to metabolism and immune regulation
Mohanty, I., Allaband, C., Mannochio-Russo, H., Abiead, Y. E., Hagey, L. R., Knight, R. D., & Dorrestein, P. C. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00914-3 · Cited by 236
“This begs 90,91,179,241 .”
Verbeke, L., Farre, R., Verbinnen, B., Covens, K., Vanuytsel, T., Verhaegen, J., Komuta, M., Roskams, T., Chatterjee, S., Annaert, P., et al. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.10.009 · Cited by 225
“FXR deficiency has therefore been linked to increased intestinal permeability and BTL in noneliver-related gastrointestinal disorders, such as inflammatory bowel disease.(25,26) However, whether FXR dysfunction also relates to BTL in chronic liver disease (and also what are the underlying pathophysiological mechanisms…”
BackgroundResultMcMahan, R. H., Wang, X. X., Cheng, L. L., Krisko, T., Smith, M., El Kasmi, K., Pruzanski, M., Adorini, L., Golden-Mason, L., Levi, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.446575 · Cited by 225
“Furthermore, FXR exerts homoeostatic functions at the interface between nutrient and lipid metabolism with innate immunity, antagonizing NF- B in hepatic inflammatory responses (17) and inhibiting intestinal inflammatory responses (16, 18).”
BackgroundInfluentialSelf-citationBile Acid Signaling in Inflammatory Bowel Diseases
Fiorucci, S., Carino, A., Baldoni, M., Santucci, L., Costanzi, E., Graziosi, L., Distrutti, E., & Biagioli, M. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06715-3 · Cited by 243
Baghdasaryan, A., Claudel, T., Gumhold, J., Silbert, D., Adorini, L., Roda, A., Vecchiotti, S., Gonzalez, F. J., Schoonjans, K., Strazzabosco, M., et al. (2011) · Hepatology · doi:10.1002/hep.24537 · Cited by 220
Self-citationRecent advances in the development of farnesoid X receptor agonists.
Ali, A. H., Carey, E. J., & Lindor, K. D. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2014.12.06 · Cited by 224
“OCA treatment reduced AST and plasma levels of interferon-ɣ and tumor necrosis factor-α in a mouse model of autoimmune hepatitis (108), reduced the expression of profibrotic and fibrosis markers in a mouse model of nephropathy (109), and attenuated colon injury by increasing colon expression of FXR and SHP and reducin…”
BackgroundBile Acid–Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside
Yang, M., Gu, Y., Li, L., Liu, T., Song, X., Sun, Y., Cao, X., Wang, B., Jiang, K., & Cao, H. (2021) · Nutrients · doi:10.3390/nu13093143 · Cited by 223
Intestinal absorption of bile acids in health and disease
Ticho, A. L., Malhotra, P., Dudeja, P. K., Gill, R. K., & Alrefai, W. A. (2019) · Comprehensive physiology · doi:10.1002/cphy.c190007 · Cited by 215
Deng, F., Peng, L., Li, Z., Tan, G., Liang, E., Chen, S., Zhao, X., & Zhi, F. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0244-8 · Cited by 208
Chen, L., Jiao, T., Liu, W., Luo, Y., Wang, J., Guo, X., Tong, X., Lin, Z., Sun, C., Wang, K., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.08.008 · Cited by 220
Kasmi, K. E., Anderson, A. L., Devereaux, M., Vue, P. M., Zhang, W.-J., Setchell, K., Karpen, S., & Sokol, R. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006898 · Cited by 201
Intestinal Barrier and Permeability in Health, Obesity and NAFLD
Portincasa, P., Bonfrate, L., Khalil, M., Angelis, M. D., Calabrese, F. M., D’Amato, M., Wang, D. Q. ‐., & Ciaula, A. D. (2021) · Biomedicines · doi:10.3390/biomedicines10010083 · Cited by 219
“FXR activation protects from chemically induced colitis and decreases gut permeability and inflammatory markers [265].”
BackgroundBile acids and colon cancer: Solving the puzzle with nuclear receptors
Degirolamo, C., Modica, S., Palasciano, G., & Moschetta, A. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.010 · Cited by 214
Self-citationDong, S., Zhu, M., Wang, K., Zhao, X., Hu, L., Jing, W., Lu, H., & Wang, S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105767 · Cited by 210
Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids
Klaassen, C. D., & Cui, J. Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065698 · Cited by 216
The cross talk between microbiota and the immune system: metabolites take center stage
Shapiro, H., Thaiss, C. A., Levy, M., & Elinav, E. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.07.003 · Cited by 189
“The beneficial effect of bile acid signaling via FXR and TGR5 comprising attenuation of pro-inflammatory innate immune response has been demonstrated in several diseases, such as non-alcoholic fatty liver disease (NAFLD) [43], LPS-induced hepatic damage and inflammation [40], atherosclerosis [41 ] and inflammatory bow…”
BackgroundAgeing of the gut microbiome: Potential influences on immune senescence and inflammageing
Conway, J., & Duggal, N. A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101323 · Cited by 202
Gadaleta, R. M., Oldenburg, B., Willemsen, E. C. L., Spit, M., Murzilli, S., Salvatore, L., Klomp, L. W. J., Siersema, P. D., van Erpecum, K. J., & van Mil, S. W. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.04.005 · Cited by 195
Self-citationBile acid signaling in the regulation of whole body metabolic and immunological homeostasis
Jia, W. P., Li, Y., Cheung, K. C.-P., & Zheng, X. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2353-0 · Cited by 207
“The attenuation effect is thought to be mediated by TGR5-induced inhibition of DCs activation through inhibition of the NF-κB activation pathway in DCs (Hu et al., 2021).”
InfluentialFXR agonists in NASH treatment
Adorini, L., & Trauner, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.034 · Cited by 200
Self-citationCrosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation
Thibaut, M. M., & Bindels, L. B. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.12.006 · Cited by 193
Update on FXR Biology: Promising Therapeutic Target?
Han, C. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072069 · Cited by 194
“In addition, FXR activation by OCA treatment inhibited the chemically induced intestinal inflammation in mice, proposing the role of FXR in the intestinal epithelial barrier in inflammatory bowel disease [95].”
BackgroundBile acids and their receptors
Martinot, E., Sèdes, L., Baptissart, M., Lobaccaro, J.-M., Caira, F., Beaudoin, C., & Volle, D. H. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.01.006 · Cited by 162
Úbeda, M., Lario, M., Muñoz, L., Borrero, M.-J., Rodríguez-Serrano, M., Sánchez-Díaz, A.-M., del Campo, R., Lledó, L., Pastor, Ó., García-Bermejo, L., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.12.010 · Cited by 178
“FXR activation by bile acids or FXR agonists maintains the mucosal integrity by regulating the expression of a variety of genes involved in mucosa protection and defense against inflammation in rodents subjected to BDL [11, 12] or dextran sulfate sodium-induced colitis [10, 18].”
BackgroundSchwabl, P., Hambruch, E., Seeland, B. A., Hayden, H., Wagner, M., Garnys, L., Strobel, B., Schubert, T.-L., Riedl, F., Mitteregger, D., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.005 · Cited by 178
Duparc, T., Plovier, H., Marrachelli, V. G., Hul, M. V., Essaghir, A., Ståhlman, M., Matamoros, S., Geurts, L., Pardo-Tendero, M., Druart, C., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310904 · Cited by 180
Metabolic programming in dendritic cells tailors immune responses and homeostasis
Møller, S. H., Wang, L., & Ho, P. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00753-1 · Cited by 189
Metadata
- Authors
- Gadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., Penna, G., Laverny, G., Adorini, L., Moschetta, A., & Mil, S. W. C. V.
- Affiliations
- University Medical Center Utrecht (NL)
- Mario Negri Sud Foundation (IT)
- Corresponding author
- Mil, Saskia W C van
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2011-01-17
- Volume
- 60
- Issue
- 4
- Pages
- 463-472
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2134059673
- Cited by
- 870
- References
- 43
- Citations by year
- 2026: 72 · 2025: 87 · 2024: 95 · 2023: 75 · 2022: 96 · 2021: 84 · 2020: 59 · 2019: 46 · 2018: 35 · 2017: 44 · 2016: 40 · 2015: 36 · 2014: 29 · 2013: 35 · 2012: 21
- FWCI
- 19.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Intercept Pharmaceuticals
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- farnesoid X receptor, FXR agonists, inflammatory bowel disease, colitis, intestinal barrier function, epithelial permeability, goblet cell loss, inflammatory cytokines, TNF-α, dendritic cells, monocytes, lamina propria, bile salts, DSS-induced colitis
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Chenodeoxycholic Acid, Colon, Disease Models, Animal, Drug Evaluation, Preclinical, Gene Expression Regulation, Humans, Ileum, Intestinal Absorption, Mice, Inbred C57BL, Trinitrobenzenesulfonic Acid, Tumor Necrosis Factor-alpha, Inflammatory Bowel Diseases, Cytokines, Dextran Sulfate, Receptors, Cytoplasmic and Nuclear, Inflammation Mediators, Caco-2 Cells, Reverse Transcriptase Polymerase Chain Reaction, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
